251 related articles for article (PubMed ID: 38699532)
1. Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma.
Ziki RA; Colnot S
JHEP Rep; 2024 May; 6(5):101077. PubMed ID: 38699532
[TBL] [Abstract][Full Text] [Related]
2. Glutamine metabolic reprogramming in hepatocellular carcinoma.
Ye Y; Yu B; Wang H; Yi F
Front Mol Biosci; 2023; 10():1242059. PubMed ID: 37635935
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.
Adebayo Michael AO; Ko S; Tao J; Moghe A; Yang H; Xu M; Russell JO; Pradhan-Sundd T; Liu S; Singh S; Poddar M; Monga JS; Liu P; Oertel M; Ranganathan S; Singhi A; Rebouissou S; Zucman-Rossi J; Ribback S; Calvisi D; Qvartskhava N; Görg B; Häussinger D; Chen X; Monga SP
Cell Metab; 2019 May; 29(5):1135-1150.e6. PubMed ID: 30713111
[TBL] [Abstract][Full Text] [Related]
5. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
7. AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation.
Liu Y; Miao Z; Yang Q
Cell Biochem Biophys; 2024 May; ():. PubMed ID: 38789662
[TBL] [Abstract][Full Text] [Related]
8. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract][Full Text] [Related]
9. Position Is Destiny: Metabolism and Cell Identity.
Goessling W
Cell Metab; 2019 May; 29(5):1017-1019. PubMed ID: 31067445
[TBL] [Abstract][Full Text] [Related]
10. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
[TBL] [Abstract][Full Text] [Related]
11. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells.
Sohn BH; Park IY; Shin JH; Yim SY; Lee JS
Exp Mol Med; 2018 Jan; 50(1):e421. PubMed ID: 29303508
[TBL] [Abstract][Full Text] [Related]
12. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract][Full Text] [Related]
13. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.
Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D
Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805
[TBL] [Abstract][Full Text] [Related]
14. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma.
Hale G; Liu X; Hu J; Xu Z; Che L; Solomon D; Tsokos C; Shafizadeh N; Chen X; Gill R; Kakar S
Mod Pathol; 2016 Nov; 29(11):1370-1380. PubMed ID: 27469330
[TBL] [Abstract][Full Text] [Related]
15. Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer.
Elmetwalli A; Nageh A; Youssef AI; Youssef M; Ahmed MAE; Noreldin AE; El-Sewedy T
Med Oncol; 2023 Dec; 41(1):38. PubMed ID: 38157146
[TBL] [Abstract][Full Text] [Related]
16. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.
Dai W; Shen J; Yan J; Bott AJ; Maimouni S; Daguplo HQ; Wang Y; Khayati K; Guo JY; Zhang L; Wang Y; Valvezan A; Ding WX; Chen X; Su X; Gao S; Zong WX
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36256480
[TBL] [Abstract][Full Text] [Related]
17. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.
Chiu M; Tardito S; Pillozzi S; Arcangeli A; Armento A; Uggeri J; Missale G; Bianchi MG; Barilli A; Dall'Asta V; Campanini N; Silini EM; Fuchs J; Armeanu-Ebinger S; Bussolati O
Br J Cancer; 2014 Sep; 111(6):1159-67. PubMed ID: 25072259
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
Schmidt A; Braeuning A; Ruck P; Seitz G; Armeanu-Ebinger S; Fuchs J; Warmann SW; Schwarz M
Toxicology; 2011 Mar; 281(1-3):7-14. PubMed ID: 21237236
[TBL] [Abstract][Full Text] [Related]
19. Critical role of glutamine metabolism in cardiomyocytes under oxidative stress.
Watanabe K; Nagao M; Toh R; Irino Y; Shinohara M; Iino T; Yoshikawa S; Tanaka H; Satomi-Kobayashi S; Ishida T; Hirata KI
Biochem Biophys Res Commun; 2021 Jan; 534():687-693. PubMed ID: 33213841
[TBL] [Abstract][Full Text] [Related]
20. Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism.
Soukupova J; Malfettone A; Hyroššová P; Hernández-Alvarez MI; Peñuelas-Haro I; Bertran E; Junza A; Capellades J; Giannelli G; Yanes O; Zorzano A; Perales JC; Fabregat I
Sci Rep; 2017 Oct; 7(1):12486. PubMed ID: 28970582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
